DNLI Live signals | Maximize Profits with Getagraph.com

BUY 102985 min ago

@ $17.66

Issued: 14 Feb 2024 @ 14:01

Return: -15.29%

Previous signal: Feb 13 - 15:45

Previous signal: Sell

Return: 3.03 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States...

Stats
Today's Volume	1.14M
Average Volume	1.25M
Market Cap	2.13B
EPS	$0 ( 2024-02-26 )
Next earnings date	( $-0.670 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.11
ATR14	$0.0250 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Sato Vicki L	Sell	1 666	Common Stock
2024-04-01	Krognes Steve E.	Sell	92 500	Common Stock
2024-03-29	Watts Ryan J.	Sell	40 000	Common Stock
2024-03-15	Sato Vicki L	Sell	1 666	Common Stock
2024-02-15	Sato Vicki L	Sell	1 666	Common Stock

INSIDER POWER
33.08
Last 100 transactions
Buy: 1 164 016 \| Sell: 631 404

Volume Correlation

Long: 0.08 (neutral)

Short: 0.79 (moderate)

Signal:(58.888) Neutral

Denali Therapeutics Inc Correlation

10 Most Positive Correlations
RUBY	0.908
ACRS	0.907
HAS	0.906
TUEM	0.902
SBRA	0.901
ALHC	0.901
SIVBP	0.897
MQ	0.897
XP	0.896
CCSI	0.896

10 Most Negative Correlations
MBIN	-0.912
SCR	-0.902
KTCC	-0.901
MPWR	-0.897
ZIONP	-0.891
HUGE	-0.889
WIRE	-0.889
ITI	-0.888
PAE	-0.888
ICPT	-0.888

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Denali Therapeutics Inc Correlation - Currency/Commodity

-0.04
( neutral )

0.01
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.33
( neutral )

-0.16
( neutral )

Denali Therapeutics Inc Financials

Annual	2023
Revenue:	$330.53M
Gross Profit:	$313.81M (94.94 %)
EPS:	$-1.060

Q4	2023
Revenue:	$0
Gross Profit:	$-2.18M (0.00 %)
EPS:	$-0.860

Q3	2023
Revenue:	$1.27M
Gross Profit:	$-950 000 (-74.98 %)
EPS:	$-0.720

Q2	2023
Revenue:	$294.12M
Gross Profit:	$292.77M (99.54 %)
EPS:	$1.340

Financial Reports:

No articles found.

Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.